Johnson & Johnson (NYSE:JNJ) Shares Sold by Dunhill Financial LLC

Dunhill Financial LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,052 shares of the company’s stock after selling 198 shares during the quarter. Dunhill Financial LLC’s holdings in Johnson & Johnson were worth $506,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tallon Kerry Patrick acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $290,000. Capital & Planning LLC grew its position in Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock valued at $221,000 after buying an additional 183 shares during the period. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $85,886,000. Finally, BXM Wealth LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $799,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $150.77 on Thursday. The stock has a market capitalization of $362.76 billion, a P/E ratio of 16.77, a PEG ratio of 2.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a 50 day moving average price of $154.06 and a 200 day moving average price of $153.67.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.45%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.